logo

For the Inventor, By the Inventor

Bryn Mawr, PA, United States of America

Julia Lynn Rutkowski

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 3.2

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:

goldMedal14 out of 14 
 
Ossianix, Inc.
 patents

Years Active: 2019-2025

Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents
1. 12351642 - TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers (2025-07-08),
2. 12297286 - Transferrin receptor (TFR)-selective binding peptides capable of crossing the blood brain barrier, encoding nucleic acids thereof and methods of use thereof (2025-05-13),
3. 12258414 - Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries (2025-03-25),
4. 12187805 - Type-II VNAR polypeptides which bind human TfR-1, encoding nucleic acids thereof and method of use thereof (2025-01-07),
5. 11918647 - TfR selective binding compounds and related methods (2024-03-05),
6. 11766482 - In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use (2023-09-26),
7. 11512136 - Transferrin receptor (TfR)-selective binding peptides capable of crossing the blood brain barrier and methods of use thereof (2022-11-29),
8. 11345742 - Shark VNARs for treating COVID-19 (2022-05-31),
9. 11339389 - Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds (2022-05-24),
10. 11267894 - BAFF selective binding compounds and related methods (2022-03-08),
11. 11097010 - In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use (2021-08-24),
12. 10722576 - TfR selective binding compounds and related methods (2020-07-28),
13. 10479990 - Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds (2019-11-19),
14. 10435474 - Baff selective binding compounds and related methods (2019-10-08),

Title: Julia Lynn Rutkowski: A Pioneer in Targeted Therapeutic Delivery

Introduction

Julia Lynn Rutkowski, an accomplished inventor based in Bryn Mawr, Pennsylvania, has made significant contributions to the fields of molecular medicine and targeted delivery systems. With a remarkable portfolio of 14 patents, Julia has demonstrated her expertise and commitment to advancing the science of therapeutics and diagnostics.

Latest Patents

Among her notable innovations are her latest patents focused on TFR-specific binding moieties and transcytosis methods designed to select VNARs that effectively cross cellular barriers. The inventions relate to enhanced TfR-binding moieties that can traverse the blood-brain barrier (BBB) and deliver therapeutic or diagnostic agents specifically targeted to brain parenchyma. Her innovative approach employs phage display libraries to develop VNARs against mammalian BBB receptors as well as receptors in other directional cell barriers. This groundbreaking work not only highlights the potential for improved treatment methods for neurological conditions but also establishes a promising avenue for drug delivery across various organs.

Career Highlights

Julia is currently employed at Ossianix, Inc., where she utilizes her extensive knowledge and innovative spirit to drive advancements in molecular medicine. Her career reflects a strong dedication to improving patient care and exploring new technologies that can benefit society at large.

Collaborations

Throughout her career, Julia has collaborated with talented individuals such as Krzysztof Bartlomiej Wicher and Pawel Stocki. These partnerships underscore the importance of teamwork in fostering innovation and achieving remarkable breakthroughs in scientific research.

Conclusion

Julia Lynn Rutkowski's pioneering work in targeted delivery systems positions her as a key figure in the realm of molecular medicine. With her continuous pursuit of innovation, she is well on her way to making lasting contributions that may transform the landscape of therapeutic and diagnostic agent delivery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…